Meet Emilie Logie

Patent Engineer

PhD in Biomedical Sciences

emilie.logie@gevers.eu


Antwerp, Brussels
Dutch, English

Experience

Emilie possesses a robust background in biomedical sciences and patent law, having transitioned from a comprehensive research career to a dynamic role as a patent engineer. Since 2021, Emilie has been actively involved in the drafting and prosecution of European patent applications within the life sciences domain. She advises and represents you for the patent landscape of competitors, freedom to operate, validity of third party’s patents, patentability of inventions, prosecution, opposition, and nullity actions. She handles cases in English and Dutch.

Education

  • PhD in Biomedical Sciences, University of Antwerp (Belgium), 2021
  • Master’s in Biomedical Sciences, University of Antwerp (Belgium), 2017

Qualifications

  • Patent Engineer
  • PhD in Biomedical Sciences

Publications

  • Logie E, Novo CP, Driesen A, Van Vlierberghe P, Vanden Berghe W. Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells. Int J Mol Sci. 2021 Nov 25;22(23):12731.
  • Logie E, Van Puyvelde B, Cuypers B, Schepers A, Berghmans H, Verdonck J, Laukens K, Godderis L, Dhaenens M, Deforce D, Vanden Berghe W. Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence. Int J Mol Sci. 2021 Nov 12;22(22):12234.
  • Logie E, Chirumamilla CS, Perez-Novo C, Shaw P, Declerck K, Palagani A, Rangarajan S, Cuypers B, De Neuter N, Mobashar Hussain Urf Turabe F, Kumar Verma N, Bogaerts A, Laukens K, Offner F, Van Vlierberghe P, Van Ostade X, Berghe WV. Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells. Cancers (Basel). 2021 Mar 31;13(7):1618.
  • Logie E, Vanden Berghe W. Tackling Chronic Inflammation with Withanolide Phytochemicals-A Withaferin a Perspective. Antioxidants (Basel). 2020 Nov 10;9(11):1107.

A question or need more information on your challenge?

Empower your
IP knowledge

Stay up to date with the latest Gevers news by signing up for our newsletter.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.